Clinical trials: Macular Telangiectasia
Macular Telangiectasia Type 2
A Phase 2 Multicenter Randomized Clinical Trial of CNTF for MacTel
This study is a phase 2, randomized, multi-center, single-masked study to evaluate the efficacy and safety of the NT-501 implants in participants with Mactel.
- Trial name
- NCT01949324
- Testing
- Ciliary neurotrophic factor (CNTF), NT-501 Implant, NT-501 Implant procedure
- Where
- 11 sites in United States, Australia
- Volunteers
- 67 people
- Sponsor
- Neurotech Pharmaceuticals
Macular Telangiectasia Type 2
Serine and Fenofibrate Study in Patients With MacTel Type 2
This is a Phase 2a study of the effect of serine supplementation and fenofibrate treatment on serum deoxysphingolipid levels in patients with macular telangiectasia type 2 (MacTel). This study involves six arms.
- Trial name
- SAFE (NCT04907084)
- Testing
- Serine, Fenofibrate
- Where
- 9 sites in United States, United Kingdom
- Volunteers
- 89 people
- Sponsor
- The Lowy Medical Research Institute Limited
Type 2 Idiopathic Macular Telangiectasia
Ranibizumab to Treat Type 2 Idiopathic Macular Telangiectasia (RAMA-Trial)
The purpose of this study is to investigate if a new drug called ranibizumab is effective to treat a rare bilateral disease of the macula: type 2 idiopathic macular telangiectasia (type 2 IMT).
- Trial name
- NCT00504400
- Testing
- Intravitreal injection ranibizumab
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- University Hospital, Bonn
Retina, Telangiectasis
Intravitreal Bevacizumab for Idiopathic Macular Telangiectasia
Idiopathic Macular Telangiectasia is characterized by incompetent and dilated retinal capillaries in the foveolar region of unknown cause for retinal telangiectasia.
- Trial name
- NCT00451763
- Testing
- Intravitreal Injection of Bevacizumab (1.25 mg/0.05ml)
- Where
- Brazil
- Volunteers
- 31 people
- Sponsor
- University of Sao Paulo
Neovascularization
Ranibizumab Injections to Treat Macular Telangiectasia With New Blood Vessel Growth
This study will examine whether the drug ranibizumab (Lucentis) can help prevent vision loss in people with macular telangiectasia, a condition in which new blood vessels grow in the retina at the back of the eye and can leak.
- Trial name
- NCT00685503
- Testing
- Ranibizumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Eye Institute (NEI)